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http://dx.doi.org/10Background and Aims. A wide spectrum of cardiovascular changes characterizes
cirrhosis, ranging from subclinical alterations to hyperkinetic syndrome. We looked for
ECG markers of ventricular repolarization in a population of patients with cirrhosis in
comparison to patients without cirrhosis and we investigated the relationship between
these and other clinical and laboratory variables.
Methods. In 149 patients with cirrhosis and 152 controls, we measured QT maximum
interval (QTmax), QT corrected interval (QTc), QT minimum interval (QTmin), QT
dispersion (QTdisp), QT peak and T peak-to-end (TpTe).
Results. In subjects with cirrhosis, in comparison with controls, we observed a higher
mean QTmax, mean QTc, mean QTmin, mean QTdisp and mean TpTe. At Cox regres-
sion analysis, diastolic blood pressure and beta-blocker treatment were significantly asso-
ciated with mean QTmax, hypertension with mean QTmin and mean QTc, diastolic blood
pressure, beta-blockers and ACE-inhibitors/ARBs with QT disp, and beta-blockers with
TpTe. Analysis of ROC curves showed a significant area under curve towards cirrhosis
diagnosis, respectively, for a cut-off value of O400 msec of QTmax, O360 msec of
QTmin, O450 msec of QTc, O105 msec of TpTe and O55 msec of QTdisp.
Conclusions. Our study shows that QT indexes are altered in cirrhotic patients and have a
potential diagnostic predictive value.  2015 IMSS. Published by Elsevier Inc.
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117Introduction
QT indexes are electrocardiographic markers of autono-
mous nervous system function and sympathovagal balance
(1,2). Recently, the presence of QT dispersion (QTdisp) on
the 12-lead electrocardiogram (ECG) has been shown to
reflect dispersion of ventricular refractoriness (3) and hasARCMED2004_proof ■ 2
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.1016/j.arcmed.2015.03.008been demonstrated to be a marker of arrhythmogenic po-
tential in the absence (4) of an acquired long QT interval.
Therefore, there is an ongoing search for other ECG
indices of repolarization, for example, by analysis of the
T-wave. One of these is Tpeak-to-Tend interval (TpTe).
TpTe and QTdisp on the ECG have been recently reported
to predict life-threatening arrhythmias in the long QT syn-
drome (5).
A wide spectrum of cardiovascular changes character-
izes liver cirrhosis ranging from the subtle subclinical alter-
ations of pre-ascitic stages to hyperkinetic syndrome
observed when decompensation develops (6,7). A prolon-
gation of QT interval has been shown in patients with-4-2015 7-59-10
Inc.
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194cirrhosis (8) but no study, to our knowledge, has evaluated
the entire range of electrocardiographic markers of ventric-
ular repolarization in cirrhotic patients.
On this basis, as primary endpoint, we looked for ECG
markers of ventricular repolarization in a population of patients
with cirrhosis in comparison with subjects without cirrhosis.
We also investigated, as primary endpoint, the
relationship between laboratory and clinical variables and
QT measurements in cirrhotic subjects.
Furthermore, in order to possibly extend the spectrum
criteria of the definition of cirrhotic cardiomyopathy,
we investigated, as secondary endpoints, the possible predic-
tive role of these ECG measurements of ventricular
repolarization towards cirrhosis diagnosis by means ROC
curves construction and their analysis.195
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234Materials and Methods
The study was carried out in accordance with the provisions
of the Declaration of Helsinki and local regulations. Keep-
ing in mind the expected frequency of QT abnormality in a
normal population at 5.9% and that in cirrhosis at 37%, a
sample size was estimated. We retrospectively analyzed
data of patients with cirrhosis consecutively admitted to
our Department of Internal Medicine from October
2004eOctober 2009 along with 152 control subjects. Con-
trol subjects were hospitalized patients without cirrhosis
admitted to our ward for other causes, during the same
period.
Cardiovascular risk factors were evaluated for both cases
and controls on the basis of the criteria shown below. Hy-
percholesterolemia was defined as the presence of total
cholesterol blood levels $200 mg/dL. Hypertension was
defined as present if subjects were previously diagnosed ac-
cording to the World Health Organization/International So-
ciety of Hypertension guidelines and were routinely
receiving antihypertensive therapy (9).
Patients were defined as having type 2 diabetes (T2D) if
they had known diabetes treated by diet, oral hypoglycemic
drugs or insulin before stroke.
Previous coronary artery disease was determined on the
basis of a history of physician-diagnosed angina, myocar-
dial infarction, or any previous revascularization procedure
assessed by a questionnaire.
CKD was defined as follows:
 Kidney damage for $3 months as defined by struc-
tural or functional abnormalities of the kidney with
or without decreased glomerular filtration rate (GFR)
that can lead to decreased GFR, manifest by either
pathological abnormalities or markers of kidney dam-
age including abnormalities in the composition of the
blood or urine or abnormalities in imaging tests
 GFR !60 mL/min/1.73 m2 for $3 months, with or
without kidney damage (10).ARCMED2004_proof ■Electrocardiogram
During retrospective analysis, we analyzed ECG data of pa-
tients with cirrhosis consecutively admitted to the Depart-
ment of Internal Medicine of our institution from October
2004eOctober 2009 and control subjects. ECG tracings
were registered during the patients’ hospital stay.
All 12-lead ECGs were recorded during supine rest and
all tracings were performed at a paper speed of 25 mm/sec
and an amplification of 10 mm/mV. On 12-lead ECG, we
measured QT maximum (QTmax), QT maximum corrected
(QTcmax), QT minimum (QTmin), QT minimum corrected
(QTcmin), QTpeak, QTdisp and TpTe. A trained observer
blinded to the subjects’ clinical data carried out the mea-
surements manually (intra-observer reproducibility as
‘‘relative errors’’ was 17%).
QT intervals were measured according to standard
criteria from the start of QRS complex to the end of the
T wave. The end of the wave was defined as the point of re-
turn to the isoelectric line. If a U wave was present, the QT
interval was measured to the nadir of the curve between the
T and the U waves. In each patient, at least nine leads had to
be clearly valuable.
QT-corrected interval (QTc) was calculated according to
Bazett’s formula:
(QTc 5 QTmax divided by U interval between two R
waves)
QTdisp (the difference between the longest and the
shortest QT interval from any lead of a 12-lead ECG)
was calculated using previously described methods (4). It
was rate corrected using the modified Bazett’s formula
(QTdispc 5 QTdisp divided by U interval between two
R waves).
The TpTe was measured in each precordial lead and ob-
tained from the difference between QT and QTpeak,
measured from the beginning of the QRS until the peak
of the T-wave. In the case of negative or biphasic T waves,
QT peak was measured to the nadir of the T-wave. T waves
!1.5 mm in amplitude were not measured. The TpTe value
reported was the maximum obtained by two observers in all
precordial leads. The measurement of each parameter was
obtained by averaging three consecutive beats (11).
Statistical Analysis
Statistical analysis of quantitative and qualitative data,
including descriptive statistics, was performed for all items.
Continuous data are expressed as mean  SD, unless other-
wise specified. Baseline differences between groups were
assessed by c2 or Fisher exact test0 as needed for categor-
ical variables, and with independent Student t test for
continuous parameters. Univariate analysis of variance
(ANOVA) was performed to compare the electrocardio-
graphic, clinical and laboratory variables between patient
groups. Items of significance were determined and then
were put through multivariate analysis to determine further2-4-2015 7-59-10
Table 1. Demographic, general and clinical variables of patients with
cirrhosis and controls Q1
Cases Controls p
Patients 149 152
M/F 86/63 90/62 0.793
Age, years; mean  SD 66.2  11.5 67.2  2.1 0.463
Diabetes, n (%) 68 (45.6) 21 (13.8) 0.0001
Hypertension, n (%) 33 (22.1) 80 (52.6) 0.0001
Sodium blood levels,
mEq/L (mean  SD)
136.6 (5.8) 137.1 (5.9) 0.390
Potassium blood levels,
mEq/L (mean  SD)
4.4 (0.8) 4.1 (1.1) 0.001
Smoking, n (%) 33 (22.1) 41 (26.9) 0.0001
Obesity, n (%) 5 (3.4) 28 (18.4) 0.0001
CAD, n (%) 14 (9.4) 14 (9.2) 0.886
Cirrhosis etiology
Alcohol, n (%) 10 (6.7)
HCV, n (%) 105 (70.5)
HBV 8 (5.4)
Cryptogenic, n (%) 7 (4.7)
HBV/HCV, n (%) 8 (5.4)
HBV þ Alcohol, n (%) 5 (3.4)
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309significance. The results were adjusted for age, T2D, hyper-
tension, smoking, obesity, peripheral artery disease (PAD),
chronic kidney disease (CKD), chronic obstructive pulmo-
nary disease (COPD), beta-blocker use, ACE-inhibitors/
angiotensin II receptor blockers (ARBs) use, nitrate use.
To assess variables that were independently predictive of
prolonged QT measurements, we used a multivariate Cox
proportional hazard regression model and nonstandardized
and standardized coefficients with their 95% confidence in-
tervals (CIs) were reported.
To assess the predictive rate of different cutoff values of
QT measurements, a receiver operating characteristic
(ROC) curve with calculations of area under the curve
and 95% CIs was constructed and sensitivity and specificity
values were calculated.
Data were analyzed by the Epi Info software v.6.0 (Cen-
ters for Disease Control and Prevention, Atlanta, GA) and
with SPSS Software v.20.0 (SPSS, Inc., Chicago, IL). All
p values were two sided; p values !0.05 were considered
statistically significant.HCV þ Alcohol, n (%) 6 (4.0)
Child Pugh score class
A, n (%) 57 (38.2)
B, n (%) 53 (35.6)
C, n (%) 39 (26.2)
Therapy
Furosemide, n (%) 84 (56.4) 41 (26.97)
Spironolactone n (%), 83 (55.7) 11 (7.23)
ACE-inhibitors/ARBs
n (%)
18 (12.8) 63 (41.44)
Beta-blockers, n (%) 42 (28.2) 28 (18.42)
Nitrates, n (%) 14 (9.4) 3 (1.91)
Neuroleptics, n (%) 4 (2.7) 6 (3.97)
Heart rate (bpm) 76.8  11.1 78.4  12.2 0.250
QTmax (msec) 415.9  39.1 375.3  30.4 !0.0005
QTc (msec) 470.6  36.6 425.7  30.5 !0.0005
QTmin (msec) 355.4  38.9 337.2  30.6 0.001
QTpeak (msec) 297.5  38.6 291.1  31.5 0.181
QTdisp (msec) 60.5  17.5 38.1  16.5 !0.0005
TpTe (msec) 108.4  25.7 84.2  20.4 !0.0005
HCV, hepatitis C virus; HBV, hepatitis B virus; QTmax, QT interval; QTc,
QT corrected; QT min, QT minimum; QTpeak, QT interval peak; QTdisp,
QT interval dispersion; TpTe, T peak-to-end.
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344Results
We enrolled 149 subjects with cirrhosis and 152 control
subjects. Demographic, general and clinical variables in
subjects with cirrhosis and in controls without cirrhosis
are listed in Table 1. Among the two groups of enrolled pa-
tients, mean age was 66.2  11.5 vs. 67.2  12.1
( p 5 0.463). With regard to cardiovascular risk factors,
68 (45.6%) vs. 21 (13.8%) ( p 5 0.0001) had T2D, 33
(22.1%) vs. 80 (52.6%) ( p 5 0.0001) had arterial hyperten-
sion, 33 (22.1%) vs. 41 (26.9%) ( p 5 0.0001) were active
smokers, five (3.4%) vs. 28 (18.4%) ( p 5 0.0001) had
obesity, 14 (9.4%) vs. 14 (9.2%) ( p 5 0.886) had previous
CAD.
In cirrhotic patients, cirrhosis etiology was: 6.7% alco-
holic, 5.4% hepatitis B-related, 70.5% hepatitis C-related,
4.7% cryptogenetic, 5.4% hepatitis B/hepatitis C-related,
3.4% hepatitis B-related/alcoholic, and 4.0% hepatitis C-
related/alcoholic. At admission, 57 (38.2%) were in
Child-Pugh A class, 53 (35.6%) Child-Pugh B class, and
39 (26.2%) Child-Pugh C class.
With regard to current therapy, 56.4% were in treatment
with furosemide, 55.7% with spironolactone, 12.8% with
ACE-inhibitors/ARBs, 28.2% with beta-blockers, 9.4%
with nitrates and 2.7% with neuroleptics.
Patients did not practice any of other drugs potentially
affecting the QT interval such as antiarrhythmic drugs, an-
tihistamines, macrolides, anxiolytic drugs, tricyclic antide-
pressants, drugs acting on the gastrointestinal motility
(cisapride, domperidone) or analgesics (methadone).
With regard to ECG variables values in cirrhotic patients
and in patients without cirrhosis, mean heart rate was
76.8  11.1 vs. 78.4  12.2 beats per minute (bpm)ARCMED2004_proof ■ 2( p 5 0.250), mean QTmax was 415.9  39.1 vs.
375.3  30.4 milliseconds (msec) ( p ! 0.0005), mean
QTc was 470.6  36.6 vs. 425.7  30.5 msec
( p ! 0.0005), mean QTmin was 355.4  38.9 vs.
337.2  30.6 msec ( p 5 0.001), mean QTpeak was
297.5  38.6 vs. 291.1  31.5 msec ( p 5 0.181), mean
QTdisp was 60.5  17.5 vs. 38.1  16.5 msec
( p ! 0.0005), mean TpTe was 108.4  25.7 vs.
84.2  20.4 msec ( p ! 0.0005). At multivariate analysis
(see Table 2; data adjusted for age, diabetes hypertension,
smoking habit, obesity PAD, COPD, beta-blockers, ACE/
ARBs, nitrates), mean QTmax, QTc, QTmin, QTdisp and
TpTe were significantly higher in patients with cirrhosis
in comparison with subjects without cirrhosis.-4-2015 7-59-10
Table 2. Multivariate analysis of electrocardiographic variables of
patients with cirrhosis and controls
Cases Controls pa
Patients 149 152
Heart rate (bpm) 76.8  11.1 78.4  12.2
QTmax (msec) 415.9  39.1 375.3  30.4 !0.0005a
QTc (msec) 470.6  36.6 425.7  30.5 !0.0005a
QTmin (msec) 355.4  38.9 337.2  30.6 0.005a
QTpeak (msec) 297.5  38.6 291.1  31.5 0.181
QTdisp (msec) 60.5  17.5 38.1  16.5 0.0001a
TpTe (msec) 108.4  25.7 84.2  20.4 !0.0005a
QTmax, QT interval; QTc, QT corrected; QT min, QT minimum; QTpeak,
QT interval peak; QTdisp, QT interval dispersion; TpTe, T peak-to-end;
PAD, peripheral artery disease; CKD, chronic kidney disease; COPD,
chronic obstructive pulmonary disease; ARBs, angiotensin receptor
blockers.
aData adjusted for age, diabetes, hypertension, smoking, obesity, PAD,
CKD, COPD, beta-blockers, ACE-inhibitors/ARBs, nitrates.
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With regard to Cox regression analysis of relationship be-
tween QT indexes and clinical and laboratory variables in
cirrhotic subjects, diastolic blood pressure (DBP)
( p 5 0.0001) and beta-blocker treatment ( p 5 0.014) were
significantly associated with mean QTmax, hypertension
with mean QTmin ( p 5 0.018) and mean QTc
( p 5 0.015), DBP ( p 5 0.001), beta-blockers
( p 5 0.002) and ACE-inhibitors/ARBs ( p 5 0.018) with
mean QTdisp, and beta-blockers ( p 5 0.004) with TpTe
(Table 3).io
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The sensitivity and specificity of QT measurements to
predict cirrhosis diagnosis is shown in Table 4. At ROC
curves analysis, with regard to predictive value of QT in-
dexes towards diagnosis of cirrhosis, the best cut-off for
the analyzed markers of ventricular dispersion were:
QTmax (sensibility: 71.99 [95% CI: 67,2e76,6], speci-
ficity: 75.13 [95% CI: 70.2e80.4], p 5 0.0001) O400
msec; QTmin (sensibility: 81.14 [95% CI: 75.2e87.3],
specificity: 55.03 [95% CI: 38.2e62.9], p 5 0.005)
O360 msec; QTc (sensibility: 74.13 [95% CI:
67.0e81.4], specificity: 73.04 [95% CI: 66.8e79.8],
p 5 0.0001) O450 msec; TpTe (sensibility: 71.38 [95%
CI: 63.0e79.5], specificity: 82.42 [95% CI: 77.2e87.8],
p 5 0.0001) O105 msec; QTdisp (sensibility: 65.6 [95%
CI: 59.7e71.8], specificity: 80.37 [95% CI: 72.2e88.6],
p 5 0.0001) O55 msec.T
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454Discussion
We reported a longer mean QTmax, QTc, QTmin, QTdisp
and TpTe in subjects with cirrhosis in comparison withARCMED2004_proof ■ 2-4-2015 7-59-11
Table 4. Predictive value of QT indexes towards cirrhosis diagnosis at ROC curves
Variable Cut-off Area under ROC curve (±SE) Sensitivity (95% CI) Specificity (95%CI) p
QTmax O400 0.704 (0.009) 71.99 (67.2e76.6) 75.13 (70.2e80.4) 0.0001
QTmin O360 0.595 (0.030) 81.14 (75.2e87.3) 55.03 (38.2e62.9) 0.005
QTc O450 0.713 (0.031) 74.13 (67.0e81.4) 73.04 (66.8e79.8) 0.0001
TpTe O105 0.722 (0.028) 71.38 (63.0e79.5) 82.42 (77.2e87.8) 0.0001
QTdisp O55 0.686 (0.032) 65.60 (59.7e71.8) 80.37 (72.2e88.6) 0.0001
QTmax, QT interval; QT min, QT minimum; QTc, QT corrected; TpTe, T peak-to-end; QTdisp, QT interval dispersion.
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564age- and sex-matched controls without cirrhosis. Whereas
these findings with regard to QTc are confirmatory of pre-
vious data (12,13), our findings of a longer QTmax,
QTmin, QTdisp and TpTe could appear original, owing
to the fact that, to our knowledge, no study has addressed
the whole spectrum of electrocardiographic markers of
ventricular repolarization in cirrhotic patients.
It has been suggested that the prolongation of the QT in-
terval in cirrhotic patients is associated with a greater
severity of liver disease. However, the populations of pa-
tients studied are heterogeneous in terms of etiology,
concomitant therapies and gender (8,14e16) and other fac-
tors that may have affected the results. Moreover, several
mechanisms may be responsible for the alterations in ven-
tricular repolarization duration in cirrhosis, such as electro-
lyte imbalance or changes in sympathetic activity and these
factors should be taken into account when QT interval is
analyzed in patients with advanced liver disease. Further-
more, results on the role of cirrhosis etiology in the genesis
of ventricular repolarization alterations seem controversial.
In a study by Bernardi et al., (8), the prevalence of QT
interval prolongation did not differ between patients with
alcohol-related cirrhosis and those with the post-viral dis-
ease. However, only 7% of patients were affected by alco-
holic cirrhosis and 12% had cirrhosis of mixed etiology. In
a study by Bal and Thuluvath (15), a prolonged QTc was
seen more commonly in patients with alcoholic cirrhosis
(60%) compared to non-alcoholic cirrhosis (35%), and
alcoholic cirrhosis was one of the independent predictors
of QT interval prolongation. A study by Genovesi et al.
(16) suggests that the alcoholic etiology may indeed play
a role in the prolongation of QT interval in cirrhotic pa-
tients, although the relatively small size of the population
does not allow a precise definition of its contribution.
In our study we had a clear majority of patients with
viral etiology and only few patients with alcoholic patho-
genesis. Despite this different distribution of etiologies
we also observed a higher mean duration of several QT
measurements that we evaluated.
In many diseases, QT interval may represent a possible
predictor of cardiovascular mortality. Among these are cor-
onary artery disease, heart failure from different etiologies,
and T2D (17e21). A longer duration of QT interval has
been associated with a higher risk of sudden cardiac deathARCMED2004_proof ■ 2and cardiovascular death in several clinical conditions
(12,22e25).
Nevertheless, sudden cardiac death is not frequent in
subjects with cirrhosis. A study conducted in subjects with
alcoholic cirrhosis showed a higher incidence of sudden
death in subjects with longer QT interval (12). Other studies
showed a higher risk of sudden cardiac death in subjects
with cirrhosis in treatment with drugs potentially linked
to lengthening of QT interval (25e27).
Although some studies have reported a longer QT inter-
val in patients with cirrhosis, no study evaluated other com-
ponents of QT interval in order to separately analyze
variables characterizing this interval. Furthermore, regard-
less of clinical severity of the disease, not all patients with
cirrhosis have a longer QTc because this finding, as re-
ported by several authors, has been observed in |50% of
cirrhotic patients (28).
For this reason, other mechanisms have been suggested
as being involved in lengthening of the QTc and the alter-
ation of myocardial repolarization indices, such as the pres-
ence of electrolyte abnormalities, the use of some drugs and
the presence of comorbidities could be involved.
We evaluated, using Cox analysis, the role of other fac-
tors such as comorbidities, other clinical variables and
drugs in terms of their association to QT measurements.
Our findings show that variables related to blood pressure
values such as a history of hypertension and a high DBP
are significantly associated, respectively, with QTmin and
QTmax duration, DBP, beta-blockers and ACE-inhibitors/
ARBs use with QTdisp, and beta-blockers use with TpTe
interval.
Studies on QTdisp in patients with cirrhosis have shown
that the lengthening of QT interval is not associated with an
increased QTdisp and on this basis some authors have sug-
gested that there could be a delay of repolarization of the
myocyte without a spatial and temporal heterogeneity of
repolarization in the same level of the ventricular wall
(29). On the other hand, studies on cardiac repolarization
in hypertensive patients have shown abnormalities mainly
due to the resulting lengthening of QT peak (30).
Another study (12) evaluated in 33 consecutive patients
with cirrhosis and 35 sex- and age-matched healthy subjects
QT intervals and QT dispersion indexes after correction for
heart rate according to Bazett’s formula. Authors analyzed-4-2015 7-59-11
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disease severity according to Child-Pugh classification
and compared these values between survivors and nonsurvi-
vors after a 3-year follow-up. Child-Pugh classification is
used to assess liver function in cirrhosis. The prevalence
of increased (O70 msec) corrected QT dispersion (QTcd)
was 45% in patients with cirrhosis. According to Child-
Pugh criteria: QTd, maximum QT interval (QTmax),
corrected QTmax (QTcmax), and QTcd in class C were
significantly higher than those of class A and B
( p! 0.05, for all comparison). Furthermore, this study re-
vealed that QT dispersion parameters were better mortality
indicators than other QT interval parameters and also may
give additional prognostic information in patients with
chronic liver disease.
The mechanisms of these alterations are different de-
pending on the condition that we take into account and
are not yet fully understood. Furthermore, in the case of
multiple co-morbidities, several more or less important
mechanisms probably come into play and then determine
the phase of repolarization ECG changes, varying accord-
ing to the predominant mechanism.
Our findings concerning a significant association be-
tween some electrocardiographic markers of ventricular
dispersion and hypertension history and DBP values could
confirm the findings of a recent study (29) showing in pa-
tients with QT interval $450 msec higher systolic and dia-
stolic pressure values. Moreover, a lengthening of QT
interval has been reported in patients with hypertensive left
ventricular hypertrophy (LVH) (30).
In addition, previous studies have reported a prolonga-
tion of action potential only (or mainly) in epicardium
(31e33) in subjects with hypertensive LVH.
Moreover, ROC curve analysis showed a significant pre-
dictive value of QTmax, QTmin, QTc, QTdisp and TpTe to-
wards diagnosis of cirrhosis. This finding could offer the
chance to use electrocardographic markers of ventricular
repolarization as possible candidate markers of cirrhosis,
opening a possible discussion about the role of cardiac
changes as an integral part of the clinical syndrome of he-
patic cirrhosis.
Our findings also raise the question, at least on the basis
of ECG, of a cirrhotic myocardiopathy independent of other
cardiovascular co-morbidities. Cirrhotic cardiomyopathy is
defined as chronic cardiac dysfunction in patients with
cirrhosis characterized by blunted contractile responsive-
ness to stress and/or altered diastolic relaxation with elec-
trophysiological abnormalities in the absence of known
cardiac disease and irrespective of the causes of cirrhosis,
although some etiologies (e.g., iron overload and alcohol
consumption) further impact on myocardial structure and
function (34).
According to some authors, QT interval prolongation
may be an important sign helpful to identify patients with
cirrhosis at risk of cirrhotic cardiomyopathy (35). AARCMED2004_proof ■recalculation of QT intervals based on heart rate and other
liver-related parameters are now indicated to better dissect
the contribution of changes in QT-interval to heart-related
morbidity and mortality in subjects with cirrhosis (36).
Nevertheless, a better comprehension of both the complex
hemodynamic changes during cirrhosis and role of comor-
bidities involved in the contractile dysfunction of the cardi-
omyocyte may lead to improved care of patients with
cirrhotic cardiomyopathy.
Some possible limitations of our study are 1) the retro-
spective design and lack of follow-up with evaluation of
possible vascular and cardiac endpoints such as cardiovas-
cular events incidence, sudden cardiac death incidence,
cardiovascular death incidence; 2) the lack of a echocardio-
graphic evaluation to evaluate a relationship between echo-
cardiographic and electrocardiographic findings; 3) Bazett’s
correction still provides a rate-dependent QTc value and
may be misleading, particularly when assessing the overall
preoperative cardiac risk and the effect of drugs affecting
the QT interval. Nevertheless, most studies concerning
QT intervals in cirrhosis used Bazett’s formula; thus in or-
der to make our findings comparable with those just pub-
lished, we used this formula to calculate QTc. Some
possible strengths of our study are diagnostic accuracy,
expertise in the reporting and existence of a control group.Conflict of Interest
None.Uncited References
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